Match tier Likely match
Presence Current · Arkansas
Last published 2021
Sources OpenAlex · ORCID
Refreshed 2026-08-08

Landry K. Kamdem

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

Researcher

Also affiliated: St. Jude Children's Research Hospital (2008); Johannes Gutenberg University Mainz (2006); Central Hospital of Yaoundé (2014); Indiana University School of Medicine (2010); Indiana University – Purdue University Indianapolis (2010–2011); University of Göttingen (2004–2006)

Faculty Researcher

14 h-index 26 pubs 1,185 cited

  • Humans
  • Female
  • Cytochrome P-450 CYP3A
  • Androstadienes
  • Postmenopause
  • Cytochrome P-450 Enzyme System
  • Polymorphism, Genetic
  • Breast Neoplasms
  • Middle Aged
  • Aromatase Inhibitors
  • Genotype
  • Microsomes, Liver
  • Pharmacogenetics
  • Animals
  • Drug-Related Side Effects and Adverse Reactions

Biography and Research Information

OverviewAI-generated summary

Landry K. Kamdem's research focuses on factors influencing endocrine therapy adherence in breast cancer patients. His work has investigated the relative contributions of drug-related and patient-related elements to treatment adherence. Kamdem has published 26 scholarly works, which have garnered over 1,184 citations, and maintains an h-index of 14. He has collaborated with Sophia Tilley, Mariam F Haji-Hersi, and Caleb A Shelton, all from Harding University Main Campus, on shared publications.

Metrics

  • h-index: 14
  • Publications: 26
  • Citations: 1,185

Selected Publications

  • Drug- and patient-related factors are the strongest predictors of endocrine therapy adherence in breast cancer patients (2021)
    Journal of Oncology Pharmacy Practice 12 citations DOI OpenAlex
  • Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion (2019)
    PMC OpenAlex
  • Effect of Aromatase Inhibition (Exemestane) on Urine Concentration of Osteoprotegerin in Healthy Postmenopausal Women (2019)
    The Journal of Clinical Pharmacology DOI OpenAlex
  • Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion (2019)
    Breast Cancer Research and Treatment 9 citations DOI OpenAlex
  • Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium (2018)
    Clinical Pharmacology & Therapeutics 138 citations DOI OpenAlex
  • Impact of the <i>OATP1B1</i> c.521T&gt;C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy post-menopausal female volunteers (2017)
    Journal of Clinical Pharmacy and Therapeutics 15 citations DOI OpenAlex
  • COX2 induction: a mechanism of endocrine breast cancer resistance? (2017)
    Breast Cancer Research and Treatment 3 citations DOI OpenAlex
  • Impact of<i>UGT2B17</i>Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy Volunteers (2015)
    The Journal of Clinical Pharmacology 20 citations DOI OpenAlex
  • Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia (2015)
    PLoS ONE 16 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

4 Collaborators 1 Institution 1 Country

Top Collaborators

View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics